Descriptor
Until 13 December 2012 Renovo was a biopharmaceutical product company in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. On that date all trading activities ceased and Renovo became an investing company as provided for by Rule 15 of the AIM Rules for Companies issued by the London Stock Exchange.
History
Founded in 1998, Renovo commenced operations in October 2000 and floated on the main market of the London Stock Exchange in April 2006. Since 24 October 2011 the company has traded on the London AIM market.
Head Office
The Manchester Incubator Building
48 Grafton Street
Manchester, M13 9XX
United Kingdom
E-mail: queries@renovo.com
Printer-friendly version